Original article
Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction
José Pedro L. Nunesa,b,, , Filipa Melãob, Ana Rita Godinhob, Joana D. Rodriguesb, Maria Júlia Maciela,b
a Faculdade de Medicina da Universidade do Porto, Porto, Portugal
b Department of Cardiology, Hospital São João, Porto, Portugal
Received 11 January 2017, Accepted 04 February 2017

Diabetes mellitus is frequently associated to cardiovascular disease. We aimed at studying the relations between anti-diabetic drugs in use at admission by diabetic patients with acute myocardial infarction and survival after a period of at least 36 and up to 52 months after admission.


Retrospective study based on electronic records. Data from a total number of 195 admissions corresponding to different patients were under analysis.


Kaplan–Meier analysis, as well as Cox analysis, failed to show a difference in survival associated to the use of DPP-4 inhibitors (n=35 patients). A non-significant trend toward increased survival was seen with metformin (n=92 patients), and in the opposite direction with both insulin (n=51 patients) and sulfonylureas (n=51 patients).


The use of DPP-4 inhibitors at admission, in patients with Diabetes mellitus admitted for acute myocardial infarction, was not associated to a different survival after no less than 36 months and up to 52 months after admission.

Acute myocardial infarction, Diabetes mellitus, DPP-4 inhibitors, Sulfonylureas

Open Access

Creative Commons License
Porto Biomedical Journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

+ info